Rep. Julie Johnson Buys Charles River Laboratories International, Inc. (NYSE:CRL) Shares

Representative Julie Johnson (D-Texas) recently bought shares of Charles River Laboratories International, Inc. NYSE: CRL. In a filing disclosed on February 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Charles River Laboratories International stock on January 15th. The trade occurred in the Representative's "MERRILL LYNCH TAX EFFICIENT CORE" account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Dell Technologies NYSE: DELL on 1/28/2025.
• Sold $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 1/28/2025.
• Sold $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 1/28/2025.
• Sold $1,001 - $15,000 in shares of ALLETE NYSE: ALE on 1/28/2025.
• Sold $1,001 - $15,000 in shares of PPG Industries NYSE: PPG on 1/27/2025.
• Purchased $1,001 - $15,000 in shares of Progressive NYSE: PGR on 1/24/2025.
• Purchased $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 1/24/2025.
• Sold $1,001 - $15,000 in shares of Chubb NYSE: CB on 1/24/2025.
• Sold $1,001 - $15,000 in shares of Morgan Stanley NYSE: MS on 1/24/2025.
• Purchased $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 1/17/2025.

Charles River Laboratories International Trading Down 0.7 %

Shares of NYSE CRL traded down $1.10 during trading hours on Monday, hitting $152.07. The company's stock had a trading volume of 841,129 shares, compared to its average volume of 1,002,698. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $275.00. The business has a 50-day simple moving average of $175.44 and a 200-day simple moving average of $189.72. The stock has a market cap of $7.78 billion, a price-to-earnings ratio of 19.03, a P/E/G ratio of 6.47 and a beta of 1.37.

Hedge Funds Weigh In On Charles River Laboratories International

A number of hedge funds have recently added to or reduced their stakes in CRL. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in Charles River Laboratories International in the 3rd quarter worth approximately $79,000. Exchange Traded Concepts LLC raised its holdings in Charles River Laboratories International by 26.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 6,049 shares of the medical research company's stock worth $1,191,000 after acquiring an additional 1,264 shares during the last quarter. Creative Planning raised its holdings in Charles River Laboratories International by 4.0% in the 3rd quarter. Creative Planning now owns 4,672 shares of the medical research company's stock worth $920,000 after acquiring an additional 180 shares during the last quarter. Wolff Wiese Magana LLC purchased a new position in Charles River Laboratories International in the 3rd quarter worth approximately $32,000. Finally, Mitchell & Pahl Private Wealth LLC raised its holdings in Charles River Laboratories International by 5.0% in the 3rd quarter. Mitchell & Pahl Private Wealth LLC now owns 3,311 shares of the medical research company's stock worth $652,000 after acquiring an additional 157 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CRL has been the subject of several research analyst reports. CLSA lowered shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price objective for the company. in a report on Monday, November 18th. The Goldman Sachs Group lowered their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. William Blair lowered shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Morgan Stanley lowered their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. Finally, Bank of America lowered their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a report on Friday, December 13th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $200.79.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas' 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. Johnson (Democratic Party) ran for election to the U.S. House to represent Texas' 32nd Congressional District. She won in the general election on November 5, 2024. Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson's career experience includes working as an attorney.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).